Business Wire

Research and Markets: Bevacizumab - Key Patent, SPC and Data Exclusivity Expiry - Covering 44 Countries

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/330598/bevacizumab_key) has announced the addition of the "Bevacizumab - Key ...
Business Insider

TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China

SUZHOU, China, Dec.1, 2021/PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHARM, 1875.HK) announced its self-developed Pusintin® (TAB008, bevacizumab injection) has been officially ...
Seeking Alpha

The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after ...

ROCKVILLIE, Md. and SUZHOU, China, May 9, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
MedPage Today

Approval of Bevacizumab Biosimilar for Ophthalmic Use Could Upend Low-Cost Anti-VEGF

CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a wide variety of off-label indications and add hundreds of millions of dollars ...